NCT04633330View on ClinicalTrials.gov

Evaluation of AHCC® for the Clearance of High Risk-HPV Infections in Chinese Female

NARecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 26, 2020

Primary Completion Date

June 30, 2024

Study Completion Date

December 31, 2024

Conditions
High Risk Human Papillomavirus InfectionLow Grade Squamous Intraepithelial Lesion
Interventions
DRUG

AHCC®capsules

AHCC®capsules, a standardized extract of cultured Lentinula edodes mycelia (ECLM) TID for 6 months after enrolment.

DRUG

Simulation of AHCC®capsules

TID for 6 months after enrolment. A compensation of AHCC®is provided to participant from control arm when HR-HPV positive at 6 months after enrolment.

Trial Locations (1)

250012

RECRUITING

Qilu Hospital of Shandong University, Jinan

All Listed Sponsors
collaborator

Qilu Hospital of Shandong University

OTHER

lead

Shandong University

OTHER